Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 39K | 19K | 22K | 0 | 0 |
| Gross Profit | 9K | 11K | 14K | 0 | 0 |
| Operating Income | -244K | -67K | -243K | -32K | 8K |
| EBITDA | -180K | -71K | -308K | 98K | 8K |
| Net Income | -433K | -231K | -426K | 6K | -70K |
| EPS (Diluted) | — | — | — | — | — |
Technology
Live Price
Offline$0.10
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → May 29, 2026
Coverage: 237 bars · Jun 20, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
StemGen, Inc. (SGNI) is a Technology stock with listed on OTC. The stock last traded around $0.10 and up 0.0% across the available one-year price window (Jun 20, 2025 → May 29, 2026). Baseline metrics include revenue growth of +101.6%, EPS growth of -15.9%, a dividend yield of 0.0%. What stands out right now is revenue +101.6%, EPS -15.9%, free cash flow -286.6% with operating margin -625.6% and ROIC 31.7%. Valuation already assumes a fairly strong business story at price/sales 117.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SGNI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGNI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGNI Max Drawdown
-99.90%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SGNI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$70.0K
-1244.7% YoY
Free Cash Flow
$7.5K
+192.8% YoY
Revenue Growth
+101.6%
EPS Growth
-15.9%
Gross Margin
21.9%
Net Margin
-1110.3%
Income statement
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 39K | 19K | 22K | 0 | 0 |
| Gross Profit | 9K | 11K | 14K | 0 | 0 |
| Operating Income | -244K | -67K | -243K | -32K | 8K |
| EBITDA | -180K | -71K | -308K | 98K | 8K |
| Net Income | -433K | -231K | -426K | 6K | -70K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1K | 236 | 3K | 0 | 635 |
| Total Assets | 402K | 397K | 390K | 0 | 635 |
| Total Liabilities | 2M | 1M | 1M | 904K | 911K |
| Shareholder Equity | -1M | -1M | -870K | -904K | -910K |
| Total Debt | 563K | 563K | 563K | 560K | 652K |
| Net Debt | 562K | 563K | 560K | 560K | 651K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8K
+192.8% YoY
Capital Expenditures
0
Free Cash Flow
8K
+192.8% YoY
Key ratios
Gross Margin
21.9%
Operating Margin
-625.6%
Net Margin
-1110.3%
ROE
35.7%
Debt / Equity
-0.42x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.